GI-6301 is under clinical development by ImmunityBio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GI-6301’s likelihood of approval (LoA) and phase transition for Chordoma took place on 14 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GI-6301 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GI-6301 overview

GI-6301 is under development for the treatment of chordoma and solid tumors including breast cancer, lung cancer, ovarian cancer, prostate cancer, colorectal tumor, pancreatic tumor, colon tumor, adenocarcinoma. The vaccine candidate is administered subcutaneously. GI-6301 is a heat-killed, recombinant yeast-based vaccine. It targets cancers expressing the brachyury protein. The vaccine candidate is based on Tarmogen technology platform. GI-6301 is a targeted molecular immunogen (Tarmogen) designed to elicit a T-cell response.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

Quick View GI-6301 LOA Data

Report Segments
  • Innovator
Drug Name
  • GI-6301
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: ImmunityBio
  • Originator: National Cancer Institute Slovakia
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.